Physician
Endocrinology
Dr. Bruce W. Bode, MD
|
|
Give Review
Bruce Bode works in the field of Endocrinology. He went to medical school at Emory University School of Medicine. Emory University School of Medicine is ranked 23 in research and 42 in primary care medicine He received 2 awards: "Top MD" and "Fellow (FACE)". Bruce W. Bode, MD is also a published doctor. He has 92 paper published. The most recent paper is: Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Bruce Bode accepts Medicare payments and is registered with Medicare.gov.
Publications
- The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System.
- Moving toward the ideal insulin for insulin pumps.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- Response to Comment on Wong et al. Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry. Diabetes Care 2014;37:2702-2709.
- Long-term Efficacy and Safety of Canagliflozin Over 104 Weeks in Patients Aged 55 to 80 Years With Type 2 Diabetes.
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared With its components given alone: results of a phase 3, open-la...
- Real-Time Continuous Glucose Monitoring Among Participants in the T1D Exchange Clinic Registry.
- Consensus statement by the american association of clinical endocrinologists/american college of endocrinology insulin pump management task force.
- Efficacy and Safety of Insulin Degludec 200 U/ML and Insulin Degludec 100 U/ML in Patients with Type 2 Diabetes (Begin: Compare).
- Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type...
- Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 Diabetes: results of two phase 3, 2...
- Threshold-based insulin-pump interruption for reduction of Hypoglycemia.
- Pathways to quality inpatient management of hyperglycemia and Diabetes: a call to action.
- The Expression of Inflammatory Genes Is Upregulated in Peripheral Blood of Patients with Type 1 Diabetes.
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 Diabetes: a pre-planned meta-analysis of phase 3 trials.
- Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with Type 1 d...
- An overview of the pharmacokinetics, efficacy and safety of liraglutide.
- Continuous glucose monitoring in 2011.
- The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 Diabetes mellitus.
- Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ???65 and <65 Years of Age: A Poo...
- Discovery and validation of serum protein changes in type 1 Diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoa...
- Teplizumab for treatment of type 1 Diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
- Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomi...
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared w...
- Association between type 1 Diabetes and GWAS SNPs in the southeast US Caucasian population.
- Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring.
- Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
- Hemoglobin A1c and mean glucose in patients with type 1 Diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomi...
- Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.
- Continuous glucose monitoring in 2010.
- Chemokine (C-C motif) ligand 2 (CCL2) in sera of patients with type 1 Diabetes and diabetic complications.
- A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 Diabetes suboptimally controlled with multiple daily injections.
- A comparison study of continuous insulin infusion protocols in the medical intensive care unit: computer-guided vs. standard column-based algorithms.
- A valuation of infusion therapy to preserve islet function in type 1 Diabetes.
- Insulin pump therapy in patients with type 2 Diabetes safely improved glycemic control using a simple insulin dosing regimen.
- Patient-reported outcomes following treatment With the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in pa...
- Understanding GLP-1 analogs and enhancing patients success.
- Insulin pump use in type 2 Diabetes.
- Individualizing care for the many: the evolving role of professional continuous glucose monitoring systems in clinical practice.
- Continuous glucose monitoring.
- Genetically dependent ERBB3 expression modulates antigen presenting cell function and type 1 Diabetes risk.
- Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
- Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 Diabetes.
- Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 Diabetes: a 52-week, ...
- Defining the importance of daily glycemic control and implications for type 2 Diabetes management.
- The effect of continuous glucose monitoring in well-controlled type 1 Diabetes.
- Liraglutide versus glimepiride monotherapy for type 2 Diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
- IFIH1 polymorphisms are significantly associated with type 1 Diabetes and IFIH1 gene expression in peripheral blood mononuclear cells.
- Self-Monitoring of Blood Glucose (SMBG) in insulin- and non-insulin-using adults with Diabetes: consensus recommendations for improving SMBG accuracy, utilization, and...
- Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio.
- Continuous glucose monitoring and intensive treatment of type 1 Diabetes.
- Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.
- Evaluation of a continuous glucose monitoring system for home-use conditions.
- Use of a computerized intravenous insulin algorithm Within a nurse-directed protocol for patients undergoing cardiovascular surgery.
- A cause-and-effect-based mathematical curvilinear model that predicts the effects of self-monitoring of blood glucose frequency on hemoglobin A1c and is suitable for s...
- Advances in hemoglobin A1c point of care technology.
- Basal insulin or premix analogue therapy in type 2 Diabetes patients.
- Working to improve care of hospital hyperglycemia through statewide collaboration: the Georgia Hospital Association Diabetes Special Interest Group.
- Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 Diabetes mellitus: insulin pump therapy versus multiple daily injections.
- Glycemic characteristics in continuously monitored patients with type 1 and type 2 Diabetes: normative values.
- Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation.
- Demonstrations and discussions of continuous glucose monitors.
- Efficacy of inhaled insulin in patients with type 2 Diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.
- Switch to multiple daily injections With insulin glargine and insulin lispro from continuous subcutaneous insulin infusion With insulin lispro: a randomized, open-labe...
- Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in Type 1 diabetic patients previo...
- Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
- Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated Diabetes: a randomized controlled trial.
- Oral insulin therapy to prevent progression of immune-mediated (type 1) Diabetes.
- Patient perception and use of an insulin injector/glucose monitor combined device.
- Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system.
- Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy.
- The suboptimal roadmap to the intensive therapy target.
- Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 Diabetes: a randomized, parallel-group, 24-week study.
- Intensive insulin therapy and insulin pumps.
- Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with Diabetes.
- Diabetes management in the new millennium using insulin pump therapy.
- Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 Diabetes.
- What's ahead in glucose monitoring? New techniques hold promise for improved ease and accuracy.
- Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 Diabetes.
- Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use.
- Clinical utility of the continuous glucose monitoring system.
- Using the continuous glucose monitoring system to improve the management of type 1 Diabetes.
- Continuous glucose monitoring used to adjust Diabetes therapy improves glycosylated hemoglobin: a pilot study.
- Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I Diabetes.
- Patient-reported experience With Velosulin human insulin in continuous subcutaneous insulin infusion.
- Computer-assisted instruction in intense insulin therapy using a mathematical model for clinical simulation With a clinical algorithm and flow sheet.
- IGF-Binding Proteins in Type-1 Diabetes Are More Severely Altered in the Presence of Complications.
- Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 Diabetes: investigator-initiated, double-blind, randomized, placebo-controlled...
- TheV-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control.
- ASPIRE In-Home: Rationale, Design, and Methods of a Study to Evaluate the Safety and Efficacy of Automatic Insulin Suspension for Nocturnal Hypoglycemia.
- Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.
Schools
Emory University School Of Medicine
Emory University Affil Hosps
Fellow American College Of Endocrinology
College of Wooster
Procedures Preformed
- Continuous Glucose Monitoring
- Insulin Pump Therapy
Conditions Treated
- Abnormal Thyroid
- Adrenal Insufficiency
- Diabetes
- Diabetes Type 1
- View All
Doctors Specialties
- Diabetes Medicine
- Internal Medicine
- Endocrinology
Accepted Insurances
Awards
- Top MD
- Fellow (FACE)
Education
-
Emory University -
Emory University School of Medicine
Hospital
-
Piedmont Hospital -
Emory Saint Joseph's Hospital of Atlanta
Drug Facts
| NPI NUMBER | 1841297751 | |
| NPPES Provider LastName | BODE | |
| NPPES Provider FirstName | BRUCE | |
| NPPES Provider ZIPCode | 303182538 | |
| NPPES Provider State | GA | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 7472.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 74.0 | |
| Percent Opioid Claims | 0.99 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841297751 |
| Last Name Of The Provider | BODE |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
|
Dr. Thomas M. Flood, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan A. Wang, MD |
|
|
Dr. Dagim M. Bekele, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Eric M. Gibney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sally A. West, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark G. Friedman, MD |
|
|
Dr. John D. Greeson, MD |
|
|
Dr. Christopher A. Newton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence S. Phillips, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Victoria C. Musey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Priya Dayamani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheryl V. Thacker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary K. Rhee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Ziemer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vin Tangpricha, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ernest W. Beasley III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sumathi Srivatsa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Justine Bode |